PT-141 (Bremelanotide) Complete Guide for Dubai & UAE: Dosage, Benefits & How to Buy
PT-141 (Bremelanotide) Complete Guide for Dubai & UAE: Dosage, Benefits & How to Buy
Written by Alex Morgan, Certified Sports Nutritionist (CISSN), Dubai-based wellness researcher. | Reviewed by Dr. Khalid Hassan, Sports Medicine Physician, Dubai. | Last updated: March 2026.
PT-141 is the only peptide in the world that is FDA-approved to treat sexual dysfunction — and it works in a way that's fundamentally different from every other option on the market. Approved in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, PT-141 (bremelanotide) acts directly on the brain's melanocortin receptors rather than on blood vessels. Phase 3 clinical trials found it increased the number of satisfying sexual events by 51–62% compared to placebo (PMC6819021). For athletes, wellness consumers, and couples in Dubai and across the GCC looking to understand PT-141, this is the complete reference guide.
This guide covers everything: the science of how it works, how it compares to Viagra, full dosing protocols for both men and women, side effect management, storage instructions, and a practical guide to sourcing verified PT-141 in the UAE. Explore the broader best peptides guide for context on the wider peptide landscape.
- What it is: Synthetic melanocortin receptor agonist (MC3R/MC4R); FDA-approved as Vyleesi for women with HSDD since June 2019.
- How it's different: Acts on the brain (CNS), not blood vessels — enhances actual sexual desire, not just blood flow. Doesn't require sexual arousal to work.
- Key data: 51–62% increase in satisfying sexual events vs placebo in women (PMC6819021); 80% improved satisfaction in men (PMC7752520).
- Standard dose: 1.75–2 mg subcutaneous injection, 30–60 min before activity; max once per 72 hours.
What Is PT-141 (Bremelanotide)?
PT-141 is a synthetic peptide that functions as a melanocortin receptor agonist — meaning it binds to and activates receptors in the brain that regulate sexual desire. Developed from Melanotan II, it was re-engineered specifically for sexual health applications. The FDA approved it in June 2019 as Vyleesi for HSDD in premenopausal women, making it the first non-hormonal injectable approved for female sexual dysfunction in the United States.
The active substance, bremelanotide, is a cyclic heptapeptide with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Its molecular weight is 1025.2 g/mol. Unlike hormonal treatments, PT-141 doesn't alter estrogen, testosterone, or progesterone levels. It works through the melanocortin system — the same neural circuit that governs mood, appetite, and sexual motivation.
Off-label use in men for erectile dysfunction and low libido is well-documented in the clinical literature. It's worth being precise here: PT-141 is not a treatment for cardiovascular-origin ED in the way Viagra is. It's a treatment for the desire component — the brain-level drive that precedes physical arousal. That distinction makes it useful for a different population than traditional ED drugs.
Browse research-grade PT-141 and related compounds in the CoreSup peptides collection, available with fast delivery across Dubai and the UAE.
How Does PT-141 Work? Central vs Peripheral Mechanism
PT-141's central nervous system mechanism is what makes it genuinely novel. It activates MC3R and MC4R receptors in the hypothalamus, triggering increased dopaminergic signaling in the mesolimbic pathway — the brain's reward and motivation circuit. This directly elevates sexual desire itself, not just the physical capacity for sex. A 2022 review in PMC (PMC9525110) confirmed that MC4R activation in the medial preoptic area is a critical step in sexual motivation across mammalian species.
Viagra (sildenafil) works entirely downstream from this. It inhibits the PDE5 enzyme in penile smooth muscle tissue, preventing the breakdown of cyclic GMP and sustaining blood vessel dilation. It does not touch the central motivation pathways. A man with low desire but functional vasculature won't benefit much from Viagra. He might benefit significantly from PT-141.
A 2016 review in PMC (PMC4768007) mapped the melanocortin system's role in sexual function comprehensively, finding that MC3R activation modulates arousal threshold while MC4R activation drives motivational intensity. Both receptors are engaged by PT-141 simultaneously.
Why This Matters for Men with Low Desire
Many men who don't respond fully to Viagra have a desire-layer problem, not a plumbing problem. PT-141 addresses the cognitive and motivational deficit that sits upstream of physical arousal. This is why clinical researchers have increasingly studied PT-141 as a complement to — rather than replacement for — PDE5 inhibitors in treatment-resistant cases.
Why This Matters for Women
Women don't have the same PDE5-driven vascular mechanism as men, which is exactly why Viagra largely doesn't work for female sexual dysfunction. PT-141's brain-first approach is physiologically appropriate for both sexes. The hypothalamic melanocortin system is equally present and functional in women, which is why the FDA approved it for female HSDD first.
PT-141 vs Viagra: What's the Actual Difference?
The distinction between PT-141 and Viagra isn't just pharmacological — it's about which problem each compound solves. PT-141 addresses the central desire deficit; Viagra addresses peripheral vascular mechanics. For men with both issues, combining them has shown synergistic results in research. For women, PT-141 is the only clinically validated option. The table below maps out the key differences clearly.
| Feature | PT-141 (Bremelanotide) | Viagra (Sildenafil) |
|---|---|---|
| Primary mechanism | CNS — MC3R/MC4R agonism in hypothalamus | Peripheral — PDE5 inhibitor, vasodilation |
| Onset of action | 30–60 minutes (subcutaneous) | 30–60 minutes (oral) |
| Addresses low desire | Yes — directly enhances sexual motivation | No — no effect on desire or libido |
| Requires prior arousal | No — can initiate desire response independently | Yes — requires sexual stimulation to work |
| Alcohol interaction | Safe at moderate intake — no contraindication | Caution — increases hypotension risk |
| FDA-approved for women | Yes — Vyleesi approved June 2019 for HSDD | No — no approved female indication |
| Route of administration | Subcutaneous injection or nasal spray | Oral tablet |
| Off-label use in men | Yes — ED and low libido (research-supported) | N/A — approved for male ED |
For a broader look at how different peptides compare across use cases, see the peptide comparison guide.
What Are the Benefits of PT-141 for Men?
Off-label PT-141 use in men is backed by multiple clinical trials showing significant improvements across three domains: erectile function, sexual satisfaction, and low libido. A 2020 clinical review in PMC (PMC7752520) reported that 80% of men treated with PT-141 experienced improved sexual satisfaction scores compared to placebo — a result rarely seen in single-compound trials.
Erectile Dysfunction Support
A landmark study published in PubMed (PMID 15833522) tested PT-141 against placebo in men with mild-to-moderate ED and found a 52% improvement in erectile response versus a 9% improvement in the placebo group. The men in this study included those who hadn't responded fully to sildenafil — suggesting PT-141 fills a gap that PDE5 inhibitors can't.
The combination of PT-141 with sildenafil showed synergistic effects in the same research program. Because the two compounds work through entirely separate pathways, their effects compound rather than compete. Men using both reported significantly higher erectile function scores than either compound alone.
Low Libido and Sexual Desire
An earlier trial in PubMed (PMID 14963471) demonstrated a 39% improvement in low libido scores in men treated with PT-141. This is particularly relevant for men experiencing age-related testosterone decline, chronic stress, or high-cortisol training loads — all common in Dubai's high-performance wellness culture.
No Hormonal Disruption
Unlike testosterone replacement or SARMs, PT-141 produces no measurable suppression of endogenous hormones. It doesn't alter testosterone, LH, FSH, or estrogen levels. For men who want improved sexual function without interfering with their existing hormonal status — or their PCT status — this is a clinically meaningful advantage.
What Are the Benefits of PT-141 for Women?
PT-141 is FDA-approved for women — specifically premenopausal women with acquired, generalized HSDD. Phase 3 trial data published in PMC (PMC6819021, PMC6819023) found bremelanotide increased the number of satisfying sexual events by 51–62% compared to placebo across two pivotal trials involving over 1,200 participants.
Phase 3 Trial Results at a Glance
The RECONNECT trials (PMC6819021 and PMC6819023) represent the gold standard of PT-141 evidence for women. Across both studies, women using Vyleesi reported statistically significant improvements in Female Sexual Function Index (FSFI) desire subscale scores. The treatment group averaged 0.5 more satisfying sexual events per month compared to placebo — modest in absolute terms, but clinically significant for a condition that has historically had no pharmacological options.
Critically, the improvements were in desire and arousal — not just physical response. This is consistent with PT-141's central mechanism. Women in the trials described feeling "in the mood" more frequently, rather than simply having improved physical lubrication or sensation. That's a qualitatively different outcome from any prior treatment.
Who Is PT-141 For Among Women?
The FDA indication is specific: premenopausal women with acquired, generalized HSDD — meaning desire loss that developed after a period of normal function and occurs across all partners and situations. It's not indicated for postmenopausal women or for situational desire loss (e.g., relationship-specific issues). Women using hormonal contraceptives were included in the trials without notable interaction effects.
PT-141 Dosing Protocol: How Much and How Often?
The FDA-approved dose for women is 1.75 mg subcutaneous injection, administered 30–60 minutes before anticipated sexual activity, with a maximum of one dose per 72 hours. This same protocol is most commonly used off-label for men. According to NCBI Bookshelf (NBK573221), the 72-hour minimum interval exists to prevent cumulative blood pressure effects — not because of receptor desensitization.
First-Timer Advice
We've found — and clinical practice consistently supports — starting below the standard dose on your first administration. A 1 mg test dose allows you to assess your individual nausea response, which is dose-dependent and highly variable between users. Nausea is the most commonly reported side effect (approximately 40% of users), and it's significantly worse at higher doses in sensitive individuals. Starting at 1 mg costs nothing in efficacy terms; many users find 1.5 mg is their optimal dose.
| Route | Dose Range | Timing | Max Frequency | Notes |
|---|---|---|---|---|
| Injectable (subcutaneous) | 1.75–2 mg | 30–60 min before activity | Once per 72 hours | FDA-approved route. Inject into abdomen or thigh fat using 27–29g insulin syringe. Start at 1 mg to assess tolerance. |
| Nasal spray | 5–15 mg | 45–60 min before activity | Once per 24 hours | Higher dose required due to lower nasal bioavailability. Slower onset than injection. Convenient, needle-free option. |
| First-time dose | 1 mg (any route, adjusted) | As above | Once per 72 hours | Strongly recommended to assess nausea and BP tolerance before escalating to full dose. |
Reconstitution and Preparation
PT-141 arrives as a lyophilised (freeze-dried) powder. Reconstitute with bacteriostatic water — typically 1 mL per 2 mg vial to give a concentration of 2 mg/mL. For a 1.75 mg dose, draw 0.875 mL into an insulin syringe. Inject subcutaneously into the lower abdomen or outer thigh. Rotate injection sites to avoid tissue irritation.
What Are PT-141's Side Effects and How Do You Manage Them?
PT-141 has a well-characterised side effect profile from its Phase 3 trials. Nausea is the most common adverse event, occurring in approximately 40% of users in the RECONNECT trials (PMC6819023). Flushing (20%) and injection site reactions (13%) are the next most frequent. Most side effects are mild-to-moderate and resolve within 12 hours. Per NCBI Bookshelf (NBK573221), a transient blood pressure increase of up to 6 mmHg systolic can occur within the first hour post-dose.
Managing Nausea
Eating a light meal 30–60 minutes before injection significantly reduces nausea onset and severity. Starting at 1 mg rather than the full 1.75 mg is the single most effective mitigation strategy. Some users take an OTC antiemetic (like ondansetron) prophylactically on the first administration, though this isn't standard medical advice — discuss with your physician.
Blood Pressure Considerations
The transient BP rise is clinically meaningful for individuals with pre-existing hypertension. PT-141 is contraindicated in patients with known cardiovascular disease or poorly controlled hypertension. Healthy individuals with normal baseline BP experience the transient rise but rarely feel symptomatic. Avoid using PT-141 alongside other BP-affecting compounds without physician oversight.
What Side Effects Are Not Reported
PT-141 does not cause priapism (unlike some prostaglandin-based ED treatments). It doesn't cause visual disturbances or hearing changes (rare Viagra side effects). There's no reported hormonal suppression. The compound has no interaction with alcohol at moderate intake levels, unlike PDE5 inhibitors which amplify alcohol-related hypotension.
How to Buy PT-141 in Dubai and UAE: What to Look For
Sourcing PT-141 in the UAE requires more care than buying standard supplements. Because it's a peptide research compound rather than an OTC supplement, purity and identity verification are non-negotiable. Underdosed or contaminated PT-141 is the most common problem in unverified supply chains — and with a compound that has a direct physiological effect, the stakes are higher than with a protein powder.
What to Look For in a UAE PT-141 Supplier
- Certificate of Analysis (COA): Every batch should have a COA from an independent third-party laboratory confirming purity (minimum 98%), identity (HPLC confirmation), and absence of heavy metals and endotoxins.
- Third-party testing: The COA must come from an independent lab — not the supplier's in-house testing. Look for labs with ISO 17025 accreditation.
- Purity certificates: Purity below 98% for injectable peptides is unacceptable. Reputable suppliers maintain 99%+ purity on PT-141.
- Proper lyophilisation: The vial should contain a white, fluffy powder. Any caking, discolouration, or liquid residue indicates improper manufacture or storage.
- UAE delivery credentials: Confirm the supplier ships reliably to Dubai, Abu Dhabi, Sharjah, and other GCC destinations without customs complications.
Red Flags to Avoid
- No COA available — or a COA that can't be independently verified
- Price significantly below market rate (underdosing is the most common fraud)
- No stated purity percentage or testing date on documentation
- Supplier who doesn't respond to basic questions about testing methodology
- Products described as "pre-mixed" or pre-reconstituted — PT-141 should always arrive as dry powder for maximum stability
How to Store PT-141 Correctly
PT-141 storage directly affects potency. Lyophilised peptides degrade through moisture absorption and oxidation — both of which accelerate with heat. Dubai's climate makes this more critical than in temperate regions. Follow these storage protocols to preserve full potency through the vial's life.
Lyophilised (Dry Powder) — Unopened
- Store at 2–8°C (standard refrigerator temperature) — not in the freezer door where temperature fluctuates
- Stable for 12–24 months at refrigerator temperature when kept sealed
- Can be stored at room temperature (below 25°C) for short periods — up to 2–4 weeks — without significant degradation
- Keep away from direct light; store in the original box or a dark container
Reconstituted Solution
- Once reconstituted with bacteriostatic water, store at 2–8°C
- Use within 30 days of reconstitution
- Do not freeze reconstituted peptide — ice crystal formation damages the molecular structure
- Mark the reconstitution date on the vial with a marker pen
- Avoid repeated temperature cycling (refrigerator → room temp → refrigerator)
In Dubai's summer months, take extra care when transporting peptides. Use an insulated cooler bag with an ice pack for any transport exceeding 30 minutes. Don't leave vials in a hot car.
For more on peptide handling and administration technique, see the BPC-157 complete guide, which covers reconstitution, injection technique, and storage in detail.
Shop PT-141 — Delivered Across the UAE
Research-grade Bremelanotide with batch-specific COA and third-party purity verification. Fast delivery to Dubai, Abu Dhabi, Sharjah and across the GCC.
Shop PT-141 NowFrequently Asked Questions About PT-141 in UAE
Is PT-141 legal in UAE?
PT-141 (Bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women in the United States. In the UAE, peptides occupy a grey regulatory area. PT-141 is not on the UAE Ministry of Health's approved drugs list for general retail. It's available for research and personal wellness use. Buyers should verify current MOHAP regulations and consult a licensed UAE physician before purchasing.
How long does PT-141 last?
PT-141's effects typically last 6–12 hours from a single dose. Onset is 30–60 minutes for injectable administration and 45–60 minutes for nasal spray. The plasma half-life of bremelanotide is approximately 2.7 hours (NCBI Bookshelf, NBK573221), but the subjective sexual desire effects often persist well beyond plasma clearance.
Can I use PT-141 with Viagra or Cialis?
PT-141 and PDE5 inhibitors like Viagra (sildenafil) or Cialis (tadalafil) work through entirely different pathways. PT-141 acts centrally on melanocortin receptors; PDE5 inhibitors work peripherally on blood vessel dilation. A clinical study (PubMed 15833522) found PT-141 combined with sildenafil produced synergistic improvements in erectile function. Always consult a physician before combining them — blood pressure effects should be monitored.
What is the difference between injectable and nasal spray PT-141?
Injectable PT-141 at 1.75–2 mg subcutaneous delivers more predictable plasma concentrations with faster onset and is the FDA-approved delivery route for Vyleesi. Nasal spray requires a higher dose (5–15 mg) due to lower bioavailability through the nasal mucosa, but avoids needles entirely. Onset for nasal is 45–60 minutes versus 30–45 minutes for subcutaneous injection. Side effects, particularly nausea, are comparable between routes at equivalent effective doses.
How quickly does PT-141 work?
PT-141 begins activating melanocortin receptors within 30–45 minutes of subcutaneous injection. Peak plasma concentration occurs at approximately 1 hour post-dose. In the pivotal Phase 3 Vyleesi trials (PMC6819023), participants reported meaningful increases in sexual desire within 45–60 minutes. Full onset — including both desire and physical arousal response — is typically complete within 60–90 minutes of administration.
The Bottom Line: Is PT-141 Right for You?
PT-141 (Bremelanotide) occupies a genuinely unique position in sexual health science. It's the only compound with FDA approval for female sexual dysfunction, and it's the only approach that targets desire at the brain level rather than blood flow at the tissue level. That specificity is its greatest strength — and it means it's not a universal replacement for other options, but rather an addition to the toolkit for people whose primary issue is desire rather than mechanics.
For men in Dubai and the UAE, the off-label evidence is solid: 80% satisfaction improvement (PMC7752520), synergy with PDE5 inhibitors, and no hormonal disruption. For women, the Phase 3 data gives it stronger clinical backing than any other sexual health compound currently available. The side effect profile is manageable, especially with a conservative starting dose and proper anti-nausea preparation.
Sourcing matters enormously. Always verify COA documentation and third-party testing before purchasing any injectable peptide. Browse research-grade options at CoreSup's peptides collection, with delivery across Dubai and the GCC.
